



CLAIMS

1. A compound of Formula (I):



- 5 or a pharmaceutically acceptable salt or solvate thereof;
 wherein:
 R^1 is selected from H, $-XR^7$, (C_1-C_6) alkyl, (C_3-C_8) cycloalkyl, and a C-linked 4-6
 membered heterocycloalkyl containing 1 to 2 heteroatoms selected from N, O and S;
 X is selected from $-CH_2-$;
- 10 R^2 is selected from H and $-SR^6$;
 R^3 is selected from H and halo;
 R^4 is selected from H and (C_1-C_3) alkyl
 R^5 is selected from H and halo;
 R^6 is methyl;
- 15 R^7 is phenyl substituted by hydroxy wherein the hydroxyphenyl is optionally further
 substituted by halo;
 provided that if R^2 is H then R^1 is XR^7 .
2. A compound according to claim 1 wherein R^1 is selected from $-XR^7$, (C_1-C_6) alkyl,
 20 (C_3-C_8) cycloalkyl, and a C-linked 4-6 membered heterocycloalkyl containing 1 to 2
 heteroatoms selected from N, O and S.
3. A compound according to claim 1 or 2 wherein R^1 is selected from (C_1-C_6) alkyl
 and (C_3-C_8) cycloalkyl.
- 25 4. A compound according to claim 3 wherein R^1 is (C_1-C_6) alkyl.

5. A compound according to claim 1 or 2 wherein R^1 is selected from $-XR^7$ and a C-linked 4-6 membered heterocycloalkyl containing 1 to 2 heteroatoms selected from N, O and S.
- 5 6. A compound according to claim 5 wherein R^1 is selected from $-XR^7$ and a C-linked 4-6 membered heterocycloalkyl containing 1 to 2 heteroatoms selected from N and O.
- 10 7. A compound according to any preceding claim wherein R^2 is $-SR^6$.
8. A compound according to any preceding claim wherein R^3 is H or fluoro.
9. A compound according to any preceding claim wherein R^4 is H.
- 15 10. A compound according to any preceding claim wherein R^5 is H or fluoro.
11. A compound according to any preceding claim wherein R^7 is phenyl substituted by hydroxy wherein the hydroxyphenyl is optionally further substituted by fluoro.
- 20 12. A compound of Formula Ia:



- 25 or a pharmaceutically salt or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 and R^5 are as defined in any preceding claim.

13. A compound according to claim wherein said compound is selected from:

- N'-cyano-6-[2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]-N-[(3R)-oxan-3-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- 5 N'-cyano-6-[2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]-N-[(oxan-3-yl)imidazo[1,2-b]pyridazine-3-carboximidamide;
- N'-cyano-N-ethyl-6-[4-fluoro-2-[5-fluoro-3-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- N'-cyano-N-ethyl-6-[4-fluoro-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- 10 N-butyl-N'-cyano-6-[4-fluoro-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- N'-cyano-N-cyclohexyl-6-[4-fluoro-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide; and
- 15 N'-cyano-6-[2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]-N-[(3-hydroxyphenyl)methyl]imidazo[1,2-b]pyridazine-3-carboximidamide;

or a pharmaceutically acceptable salt or solvate thereof.

20 14. A compound according to claim wherein said compound is selected from:

- (Z)-N'-cyano-6-[(2R)-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]-N-[(3R)-oxan-3-yl]imidazo[1,2-b]pyridazine-3-carboximidamide ;
- (Z)-N'-cyano-6-[(2R)-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]-N-[(3S)-oxan-3-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- 25 (Z)-N'-cyano-N-ethyl-6-[(2R,4S)-4-fluoro-2-[5-fluoro-3-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- (Z)-N'-cyano-N-ethyl-6-[(2R,4S)-4-fluoro-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- 30 (Z)-N-butyl-N'-cyano-6-[(2R,4S)-4-fluoro-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- (Z)-N'-cyano-N-cyclohexyl-6-[(2R,4S)-4-fluoro-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboximidamide; and
- (Z)-N'-cyano-6-[(2R)-2-[5-fluoro-2-(methylsulfanyl)phenyl]pyrrolidin-1-yl]-N-[(3-hydroxyphenyl)methyl]imidazo[1,2-b]pyridazine-3-carboximidamide;
- 35

or a pharmaceutically acceptable salt or solvate thereof.

15. A pharmaceutical composition comprising a compound according to any of claims 1 to 14 and one or more pharmaceutically acceptable excipients.

5

16. A pharmaceutical composition according to claim 15 in combination with one or more other therapeutic agents.

17. A compound according to any of claims 1 to 14 for use as a pharmaceutical.

10

18. A compound as defined in any of the preceding claims for use in treating or preventing a condition or disorder which is mediated by Trk.

19. A compound according to claim 18 for use according to claim 18 wherein the
15 condition or disorder is mediated by TrkA, TrkB, and TrkC.

20. A compound according to claim 18 or 19 for use according to claim 18 or 19 wherein the condition or disorder is atopic dermatitis.

20 21. Use of a compound as defined in any of claims 1 to 14 in the manufacture of a medicament for treating or preventing a condition or disorder which is mediated by Trk.

22. Use according to claim 21 wherein the condition or disorder is mediated by TrkA, TrkB, and TrkC.

25

23. Use according to claim 21 or 22 wherein the condition or disorder is atopic dermatitis.

24. A method for preventing or treating a condition or disorder which is mediated by
30 Trk which comprises administering to a subject in need thereof a therapeutically effective amount of a compound as defined in any of claims 1 to 14.

25. A method according to claim 24 wherein the condition or disorder is mediated by TrkA, TrkB, and TrkC.

35 26. A method according to claim 24 or 25 wherein the condition or disorder is atopic dermatitis.